Deep graph contrastive learning model for drug-drug interaction prediction.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2024
2024
Historique:
received:
20
02
2024
accepted:
17
05
2024
medline:
17
6
2024
pubmed:
17
6
2024
entrez:
17
6
2024
Statut:
epublish
Résumé
Drug-drug interaction (DDI) is the combined effects of multiple drugs taken together, which can either enhance or reduce each other's efficacy. Thus, drug interaction analysis plays an important role in improving treatment effectiveness and patient safety. It has become a new challenge to use computational methods to accelerate drug interaction time and reduce its cost-effectiveness. The existing methods often do not fully explore the relationship between the structural information and the functional information of drug molecules, resulting in low prediction accuracy for drug interactions, poor generalization, and other issues. In this paper, we propose a novel method, which is a deep graph contrastive learning model for drug-drug interaction prediction (DeepGCL for brevity). DeepGCL incorporates a contrastive learning component to enhance the consistency of information between different views (molecular structure and interaction network), which means that the DeepGCL model predicts drug interactions by integrating molecular structure features and interaction network topology features. Experimental results show that DeepGCL achieves better performance than other methods in all datasets. Moreover, we conducted many experiments to analyze the necessity of each component of the model and the robustness of the model, which also showed promising results. The source code of DeepGCL is freely available at https://github.com/jzysj/DeepGCL.
Identifiants
pubmed: 38885206
doi: 10.1371/journal.pone.0304798
pii: PONE-D-24-06815
pmc: PMC11182529
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0304798Informations de copyright
Copyright: © 2024 Jiang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Sci Transl Med. 2012 Mar 14;4(125):125ra31
pubmed: 22422992
Bioinformatics. 2021 Sep 29;37(18):2988-2995
pubmed: 33769494
Biomed Res Int. 2014;2014:196858
pubmed: 25147789
Chem Sci. 2022 Jul 13;13(29):8693-8703
pubmed: 35974769
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 33940598
Bioinformatics. 2015 Jun 15;31(12):2007-16
pubmed: 25667546
BMC Bioinformatics. 2021 Jul 24;22(1):385
pubmed: 34303360
Bioinformatics. 2021 Sep 9;37(17):2651-2658
pubmed: 33720331
BMC Bioinformatics. 2019 Dec 18;20(1):726
pubmed: 31852427
BMC Bioinformatics. 2022 Jun 10;23(1):224
pubmed: 35689200
PLoS Comput Biol. 2013;9(9):e1003226
pubmed: 24068907
KDD. 2016 Aug;2016:855-864
pubmed: 27853626
Brief Bioinform. 2021 Nov 5;22(6):
pubmed: 33951725
Comput Struct Biotechnol J. 2024 Feb 15;23:1016-1025
pubmed: 38425487
Br J Clin Pharmacol. 2021 Nov;87(11):4051-4100
pubmed: 33769581
Front Pharmacol. 2022 Jan 28;12:814858
pubmed: 35153767
Cancers (Basel). 2021 Jan 07;13(2):
pubmed: 33430223
Brief Bioinform. 2022 Jan 17;23(1):
pubmed: 34671814
Molecules. 2022 Mar 03;27(5):
pubmed: 35268770
Proc Natl Acad Sci U S A. 2018 May 1;115(18):E4304-E4311
pubmed: 29666228
Sci Rep. 2022 Sep 16;12(1):15590
pubmed: 36114278
Brief Bioinform. 2022 Jul 18;23(4):
pubmed: 35667078
Brief Bioinform. 2022 Jan 17;23(1):
pubmed: 34571537
iScience. 2023 Sep 22;26(10):108020
pubmed: 37854693
J Chem Inf Model. 2010 May 24;50(5):742-54
pubmed: 20426451
Brief Bioinform. 2023 Jan 19;24(1):
pubmed: 36592061
Interdiscip Sci. 2021 Jun;13(2):299-311
pubmed: 33611781
Brief Bioinform. 2022 Jan 17;23(1):
pubmed: 34695842